细胞外基质重塑血清标志物可预测原发性硬化性胆管炎无移植生存
研究评估四种基底膜与间质细胞外基质重塑标志物在138例大胆管型原发性硬化性胆管炎患者(其中102例[74%]合并炎症性肠病)中的预后价值,并设52例溃疡性结肠炎患者为对照。中位随访2.2年(范围0-4.3年)。所有标志物在原发性硬化性胆管炎中均高于溃疡性结肠炎患者(P<0.001),PRO-C3组间差异最大,为溃疡性结肠炎患者的3倍。除C3M外,基线血清标志物水平高的患者生存期短于水平低的患者(P<0.001)。联合PRO-C3与PRO-C5预测无移植生存的比值比为47,而增强肝纤维化试验的比值比为11。
要点
- PRO-C3在原发性硬化性胆管炎中较溃疡性结肠炎升高3倍,组间差异最大。
- 除C3M外,基线标志物高水平患者生存期短于低水平患者(P<0.001)。
- 联合PRO-C3与PRO-C5预测无移植生存的比值比为47,增强肝纤维化试验为11。
核心结论
- 原发性硬化性胆管炎患者细胞外基质重塑高于溃疡性结肠炎患者,间质基质标志物PRO-C3被确定为强效预后标志物及无移植生存的独立预测因子。
研究设计与样本
- 血清样本来自2008-2012年招募的138例大胆管型原发性硬化性胆管炎患者(其中102例[74%]合并炎症性肠病)和52例溃疡性结肠炎患者(对照),中位随访2.2年(范围0-4.3年)。
- 检测III型和V型胶原形成标志物(分别为PRO-C3和PRO-C5)及III型和IV型胶原降解标志物(分别为C3M和C4M),并以增强肝纤维化试验作比较。
主要发现
- 所有标志物在原发性硬化性胆管炎中均高于溃疡性结肠炎患者(P<0.001)。
- PRO-C3组间差异最大,原发性硬化性胆管炎较溃疡性结肠炎患者升高3倍。
- 除C3M外,基线血清标志物水平高的患者生存期短于水平低的患者(P<0.001)。
- 联合PRO-C3与PRO-C5预测无移植生存的比值比为47,增强肝纤维化试验的比值比为11。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primary sclerosing cholangitis is a progressive liver disease with a remarkably variable course. Biomarkers of disease activity or prognostic models predicting outcome at an individual level are currently not established. AIM: To evaluate the prognostic utility of four biomarkers of basement membrane and interstitial extracellular matrix remodeling in patients with primary sclerosing cholangitis. METHODS: Serum samples were available from 138 large-duct primary sclerosing cholangitis patients (of which 102 [74%] with IBD) recruited 2008-2012 and 52 ulcerative colitis patients (controls). The median follow-up time was 2.2 (range 0-4.3) years. Specific biomarkers of type III and V collagen formation (PRO-C3 and PRO-C5, respectively) and type III and IV collagen degradation (C3M and C4M, respectively) were assessed. The Enhanced Liver Fibrosis test, including procollagen type III N-terminal peptide, tissue inhibitor of metalloproteinase-1 and hyaluronic acid was assessed for comparison. RESULTS: All markers were elevated in primary sclerosing cholangitis compared to ulcerative colitis patients (P < 0.001). PRO-C3 showed the largest difference between the two groups with a threefold increase in primary sclerosing cholangitis compared to ulcerative colitis patients. Patients with high baseline serum levels of all markers, except C3M, had shorter survival compared to patients with low baseline serum levels (P < 0.001). Combining PRO-C3 and PRO-C5 the odds ratio for predicting transplant-free survival was 47 compared to the Enhanced Liver Fibrosis test's odds ratio of 11. CONCLUSIONS: Extracellular matrix remodeling is elevated in primary sclerosing cholangitis patients compared to ulcerative colitis patients. Furthermore, the interstitial matrix marker PRO-C3 was identified as a potent prognostic marker and an independent predictor of transplant-free survival in primary sclerosing cholangitis.
引用
- Nielsen MJ, Thorburn D, Leeming DJ, et al. Serological markers of extracellular matrix remodeling predict transplant-free survival in primary sclerosing cholangitis. Aliment Pharmacol Ther. 2018. PMID: 29851098. doi:10.1111/apt.14806
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。